We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+4.26%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$152M
AUM Growth
-$10.9M
Cap. Flow
-$13.9M
Cap. Flow %
-9.19%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$88.3M 58.16%
3,959,440
– –
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$23.3M 15.32%
273,077
– –
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$17.3M 11.42%
1,159,425
-993,667
-46% -$13.9M
ATXS
4
DELISTED
Astria Therapeutics
ATXS
$9.94M 6.55%
45,875
– –
VBIV
5
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$8.34M 5.49%
89,701
– –
EPIX
6
DELISTED
ESSA Pharma
EPIX
$4.64M 3.06%
106,061
– –

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q4 2016 Portfolio in Review

As of Q4 2016, Clarus Ventures held 6 positions worth $152M, down 6.7% from $163M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures withdrew a net $13.9M in Q4 2016, reducing 1 holding. Its largest reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's biggest Q4 2016 reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $13.9M.
  • Clarus Ventures's ten largest holdings make up 100% of its $152M portfolio in Q4 2016.
  • Clarus Ventures opened 0 new positions and closed 0 in Q4 2016.
  • Clarus Ventures's portfolio value fell 6.7% quarter-over-quarter to $152M.

Based on Clarus Ventures's 13F filing for Q4 2016, filed 13 Feb 2017.